FDA Leadership Shake-up: Hoeg Removed
Analysis based on 17 articles · First reported May 15, 2026 · Last updated May 17, 2026
The leadership shake-up at the United States — Food and Drug Administration, including the removal of Tracy Beth Høeg and resignations of Marty Makary and Vinay Prasad, introduces uncertainty regarding future regulatory policies for pharmaceuticals and biotechnology. This instability could lead to increased scrutiny or delays for drug approvals, potentially impacting publicly traded companies in the healthcare sector.
Dr. Tracy Beth Høeg, acting drug center director at the United States — Food and Drug Administration, was removed from her position, following her controversial inquiries into the safety of antidepressants and COVID-19 vaccines. This departure is part of a broader leadership shake-up at the United States — Food and Drug Administration, which also saw Commissioner Marty Makary resign and vaccine chief Vinay Prasad step down. Hoeg's rapid ascent within the agency was orchestrated by Makary, and her tenure was marked by investigations reflecting her pre-government concerns, including criticisms of masking and vaccine mandates. The changes at the United States — Food and Drug Administration are linked to complaints from Donald Trump's political allies regarding the agency's direction.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard